Aprepitant

Generic Name
Aprepitant
Brand Names
Aponvie, Cinvanti, Emend
Drug Type
Small Molecule
Chemical Formula
C23H21F7N4O3
CAS Number
170729-80-3
Unique Ingredient Identifier
1NF15YR6UY
Background

Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...

Indication

For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).

Associated Conditions
Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
Associated Therapies
-
Clinical Trials
Related News

Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

First Posted Date
2019-03-15
Last Posted Date
2019-03-15
Lead Sponsor
Mahidol University
Target Recruit Count
147
Registration Number
NCT03876938
Locations
🇹🇭

Division of medical oncology, department of medicine Siriraj Hospital, Bangkok, Thailand

🇹🇭

Siriraj Hospital, Bangkok, Thailand

Phase 2 Bunionectomy HTX-011 Administration Study

First Posted Date
2018-10-24
Last Posted Date
2023-06-26
Lead Sponsor
Heron Therapeutics
Target Recruit Count
78
Registration Number
NCT03718039
Locations
🇺🇸

Endeavor Clinical Trials, LLC, San Antonio, Texas, United States

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

First Posted Date
2018-09-17
Last Posted Date
2023-02-08
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
248
Registration Number
NCT03674294
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

First Posted Date
2018-06-28
Last Posted Date
2020-07-15
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
44
Registration Number
NCT03572829
Locations
🇨🇳

National Cancer Center/ Cancer Hospital, Chinese Academy of Medcal science and Peking Union Medical College, Beijing, China

"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

First Posted Date
2017-07-17
Last Posted Date
2019-08-20
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Target Recruit Count
240
Registration Number
NCT03219710
Locations
🇮🇳

Dr Bra Irch, Aiims, New Delhi, New Delhi, Delhi, India

Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Aprepitant
First Posted Date
2016-12-12
Last Posted Date
2018-12-12
Lead Sponsor
Mayo Clinic
Target Recruit Count
27
Registration Number
NCT02989467
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy

First Posted Date
2016-12-01
Last Posted Date
2017-01-25
Lead Sponsor
Dr Atul Sharma
Target Recruit Count
116
Registration Number
NCT02979548
Locations
🇮🇳

Irch, Aiims , New Delhi , India, New Delhi, DEL, India

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

First Posted Date
2016-05-12
Last Posted Date
2021-10-05
Lead Sponsor
University of Ulm
Target Recruit Count
10
Registration Number
NCT02770378
Locations
🇩🇪

University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

First Posted Date
2016-01-05
Last Posted Date
2021-05-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
138
Registration Number
NCT02646020
Locations
🇨🇳

Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Not Applicable
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
Procedure: Automated recommendation at the start of the case
Procedure: Automated notification at the start of surgery
Procedure: Automated notification at the end of surgery
Device: Anesthesia Information Management System (AIMS)
Device: Perioperative Data Warehouse (PDW)
Procedure: General anesthesia
Procedure: Elective surgery
Drug: Propofol
Drug: Sevoflurane
Drug: Isoflurane
Drug: Desflurane
Drug: Scopolamine
Drug: Droperidol
Drug: Haloperidol
Drug: Dexamethasone
Drug: Promethazine
Drug: Meclizine
Drug: Aprepitant
Drug: Metoclopramide
Drug: Fentanyl
Drug: Sufentanil
Drug: Alfentanil
Drug: Remifentanil
Drug: Morphine
Drug: Meperidine
Drug: Hydromorphone
Drug: Methadone
Drug: Oxycodone
Drug: Oxymorphone
Drug: Hydrocodone
Drug: Ketamine
Drug: Ondansetron
Drug: Granisetron
Drug: Dolasetron mesylate
Drug: Palonosetron
Drug: Tropisetron
Drug: Ramosetron
First Posted Date
2015-12-09
Last Posted Date
2019-03-07
Lead Sponsor
Vanderbilt University
Target Recruit Count
27034
Registration Number
NCT02625181
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy